Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

Pharvaris N.V. PHVS

Healthcare  —  Biotechnology
32.02 (0.97) (2.94%) as of 25 Sep
Market cap
$2.3B
P/E
0.0×
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Pharvaris N.V. (PHVS) Business Profile

Updated before January 2025

Company Overview

Pharvaris N.V. (PHVS) is a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for rare diseases. Founded in 2015, the company is headquartered in Leiden, the Netherlands, with additional operations in Zug, Switzerland. Pharvaris was established by a team of seasoned pharmaceutical executives and scientists, including co-founders Berndt Modig and Jochen Knolle, who bring decades of experience in drug development and commercialization. The company is led by a strong leadership team, with Berndt Modig serving as Chief Executive Officer and Jochen Knolle as Chief Scientific Officer. Pharvaris is committed to addressing unmet medical needs through the development of novel, orally available small molecules.

Core Business Segments

Pharvaris focuses on the development of therapies for hereditary angioedema (HAE), a rare genetic disorder characterized by recurrent episodes of severe swelling. The company’s primary product candidate is PHA121, an oral bradykinin B2 receptor antagonist designed to prevent and treat HAE attacks. PHA121 is being developed in multiple formulations to address both acute and prophylactic treatment needs:

  • PHA121 for Acute Treatment: This formulation is intended to provide rapid relief during HAE attacks, offering a convenient alternative to injectable therapies.
  • PHA121 for Prophylaxis: This version aims to prevent HAE attacks, improving the quality of life for patients by reducing the frequency and severity of episodes.

Pharvaris is also exploring additional indications for its bradykinin B2 receptor antagonist platform, leveraging its expertise in small-molecule drug development to expand its pipeline.

Business Model

Pharvaris operates as a research-driven biopharmaceutical company, focusing on the discovery, development, and commercialization of innovative therapies for rare diseases. The company’s business model is centered on:

  1. Research and Development (R&D): Pharvaris invests heavily in R&D to advance its pipeline of oral therapies. The company collaborates with academic institutions, research organizations, and industry partners to accelerate drug discovery and development.
  2. Clinical Trials: Pharvaris conducts rigorous clinical trials to demonstrate the safety and efficacy of its product candidates. The company’s clinical programs are designed to meet regulatory requirements in key markets, including the United States and Europe.
  3. Commercialization: Once approved, Pharvaris plans to commercialize its therapies through a combination of in-house sales teams and strategic partnerships. The company aims to establish a strong presence in the rare disease market, leveraging its expertise in HAE to build a sustainable business.

Revenue generation will primarily come from product sales, with additional income from licensing agreements and potential collaborations with other pharmaceutical companies.

Strategic Direction

Pharvaris is focused on becoming a leader in the treatment of HAE and other rare diseases. The company’s strategic priorities include:

  • Advancing PHA121: Pharvaris is committed to completing clinical development and obtaining regulatory approval for its lead product candidate. The company is conducting multiple clinical trials to evaluate the safety and efficacy of PHA121 in both acute and prophylactic settings.
  • Expanding the Pipeline: Pharvaris aims to leverage its bradykinin B2 receptor antagonist platform to develop therapies for additional indications. The company is exploring opportunities in other rare diseases and conditions involving bradykinin-mediated pathways.
  • Sustainability Goals: Pharvaris is dedicated to operating in an environmentally and socially responsible manner. The company is implementing sustainable practices across its operations and prioritizing patient access to its therapies.
  • Global Expansion: Pharvaris plans to establish a global presence by entering new markets and forming strategic partnerships with regional and international pharmaceutical companies.

Competitive Landscape

Pharvaris operates in a competitive market, facing competition from both established pharmaceutical companies and emerging biotechs. Key competitors in the HAE space include:

  • Takeda Pharmaceutical Company: Takeda is a global leader in HAE treatment, offering products such as Takhzyro (lanadelumab) and Firazyr (icatibant).
  • BioCryst Pharmaceuticals: BioCryst has developed Orladeyo (berotralstat), an oral therapy for HAE prophylaxis.
  • CSL Behring: CSL Behring provides HAE treatments such as Haegarda and Berinert.

Pharvaris differentiates itself through its focus on oral therapies, which offer significant advantages in terms of convenience and patient adherence compared to injectable treatments.

Risk Factors

Pharvaris faces several risks that could impact its business and financial performance:

  • Regulatory Risks: The approval process for new drugs is complex and uncertain. Delays or failures in obtaining regulatory approval could hinder the company’s ability to commercialize its products.
  • Market Dependence: Pharvaris is heavily reliant on the success of PHA121. Any setbacks in its development or commercialization could have a significant impact on the company’s prospects.
  • Competition: The HAE market is highly competitive, with established players and new entrants vying for market share. Pharvaris must demonstrate the superiority of its therapies to succeed.
  • Supply Chain Disruptions: The company depends on third-party manufacturers and suppliers for the production of its product candidates. Disruptions in the supply chain could delay clinical trials or product launches.
  • Financial Risks: As a clinical-stage company, Pharvaris does not yet generate revenue from product sales. The company relies on external funding to finance its operations, which may not be sustainable in the long term.

Recent Developments

Pharvaris has made significant progress in advancing its pipeline and corporate strategy:

  • Clinical Trials: The company recently announced positive interim results from its Phase 2 clinical trial of PHA121 for acute HAE treatment. These results demonstrate the potential of PHA121 to provide rapid and effective relief during HAE attacks.
  • Regulatory Milestones: Pharvaris has engaged with regulatory authorities in the United States and Europe to discuss the development and approval pathway for PHA121.
  • Corporate Partnerships: The company has entered into strategic collaborations with leading research institutions to explore new applications for its bradykinin B2 receptor antagonist platform.
  • Global Developments: The COVID-19 pandemic has highlighted the importance of patient-centric therapies, reinforcing Pharvaris’s commitment to developing convenient, oral treatments for rare diseases.

Investment Considerations

Pharvaris offers several strengths and risks for potential investors to consider:

Strengths:

  • Innovative Pipeline: Pharvaris is developing a first-in-class oral therapy for HAE, addressing a significant unmet medical need.
  • Experienced Leadership: The company is led by a team of seasoned executives with a proven track record in drug development and commercialization.
  • Strong Market Potential: The global HAE market is expected to grow significantly in the coming years, providing a substantial opportunity for Pharvaris.

Risks:

  • Clinical and Regulatory Uncertainty: The success of Pharvaris depends on the approval and commercialization of its product candidates, which are subject to rigorous clinical and regulatory scrutiny.
  • Financial Dependence: As a pre-revenue company, Pharvaris relies on external funding to finance its operations, which may not be sustainable in the long term.
  • Competitive Pressure: The HAE market is highly competitive, with established players and new entrants vying for market share.

Conclusion

Pharvaris N.V. is a promising biopharmaceutical company with a strong focus on developing innovative therapies for rare diseases. The company’s lead product candidate, PHA121, has the potential to transform the treatment landscape for HAE by offering a convenient, oral alternative to injectable therapies. While Pharvaris faces significant risks, including regulatory and financial challenges, its innovative pipeline, experienced leadership, and strong market potential position it for long-term success. As the company advances its clinical programs and prepares for commercialization, it is well-positioned to become a leader in the rare disease market.